Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Meningioma × vistusertib × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Neoplasms 3 Stomach Neoplasms 2 Solid Tumor 2 Small Cell Lung Carcinoma 2 Recurrence 2 Lymphoma, Large B-Cell, Diffuse 2 Lymphoma 2 Carcinoma, Non-Small-Cell Lung 2 Breast Neoplasms 2 Triple Negative Breast Neoplasms 1 Prostatic Neoplasms 1 Non-small Cell Lung Cancer Metastatic 1 Neoplasm Metastasis 1 Muscle Invasive Bladder Cancer 1 Meningioma 1 Lung Neoplasms 1 Glioblastoma 1 Estrogen Receptor Positive Breast Cancer 1 Endometrial Neoplasms 1 Disease 1 DLBCL 1 Carcinoma, Squamous Cell 1 Carcinoma, Renal Cell 1 Carcinoma 1 Advanced Solid Malignancies 1 Advanced Metastatic Breast Cancer 1 Advanced Cancer 1 Adenocarcinoma 1

Interventions

Magnetic Resonance Spectroscopy 14 Hydroxyurea 7 Everolimus 7 lutetium Lu 177 dotatate 6 gallium Ga 68 dotatate 6 Radiosurgery 6 Proton Therapy 6 Specimen Handling 5 Bevacizumab 5 pembrolizumab 4 Surveys and Questionnaires 4 Radiotherapy 4 Imatinib Mesylate 4 Cyclophosphamide 4 abemaciclib 3 Tranexamic Acid 3 Temozolomide 3 Surgical Procedures, Operative 3 Sunitinib 3 Radiotherapy, Intensity-Modulated 3 Observation 3 Nivolumab 3 Ga(III)-DOTATOC 3 90Y-octreotide, DOTA-Tyr(3)- 3 trametinib 2 fludarabine 2 arginyllysine 2 aldesleukin 2 Yoga 2 Whole Body Imaging 2

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03071874 2022-10-18

Vistusertib (AZD2014) For Recurrent Grade II-III Meningiomas

Massachusetts General Hospital

Phase 2 Unknown

Meningioma

Data powered by HemOnc (CC BY 4.0) Colophon ⚡